Hahn-Sun Jung

Title: Innovations of Hahn-Sun Jung in Angiogenesis Inhibition

Introduction

Hahn-Sun Jung is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit angiogenesis. With a total of 2 patents to his name, his work is paving the way for advancements in medical treatments.

Latest Patents

Hahn-Sun Jung's latest patents include a compound having angiogenesis inhibitory activity and a method for producing target proteins using amino acids and pyruvic acids in the culture of plant cells. The first patent discloses an anti-angiogenic compound, represented by Chemical Formula I, which potently suppresses angiogenesis. This compound is applicable for the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor, making it a valuable anti-angiogenic agent. The second patent provides a method for producing a target protein via the cultivation of transgenic plant cells. This method allows for the expression of the target protein under sugar-free conditions, enhancing the efficiency of protein production.

Career Highlights

Hahn-Sun Jung is currently associated with Boryung Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on developing new therapeutic agents that can address critical health issues.

Collaborations

Hahn-Sun Jung collaborates with esteemed colleagues such as Seung-Hoon Kang and Sang-Lin Kim. Their combined expertise contributes to the advancement of research and development in their field.

Conclusion

Hahn-Sun Jung's contributions to the field of pharmaceuticals, particularly in angiogenesis inhibition, highlight his role as an influential inventor. His innovative patents and ongoing work at Boryung Pharmaceutical Co., Ltd. are set to make a significant impact on medical treatments in the future.